FGP
KMTS

Freestone Grove Partners’s Kestra Medical Technologies KMTS Stock Holding History

Freestone Grove Partners’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,083
Closed -$326K – 885
2025
Q1 		$326K Buy
+13,083
New +$301K ﹤0.01% 462

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Freestone Grove Partners's KMTS Position: Q2 2025 in Review

Freestone Grove Partners sold out of Kestra Medical Technologies (KMTS) in Q2 2025, closing a stake of 13,083 shares — an estimated $326K sold.

Freestone Grove Partners first reported a position in KMTS in Q1 2025 and held it in 1 quarter. The position peaked at $326K in Q1 2025. 73 funds tracked by Wall St. Rank hold KMTS as of Q2 2025.

  • Freestone Grove Partners reported no remaining Kestra Medical Technologies position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 13,083 Kestra Medical Technologies shares in Q2 2025, an estimated $326K.
  • Freestone Grove Partners first reported a position in Kestra Medical Technologies in Q1 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Kestra Medical Technologies position peaked at $326K in Q1 2025.
  • 73 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.